On October 30, 2020, the company Regeneron announced that an independent data monitoring committee overseeing the clinical trials recommended that the company cease enrolling hospitalized patients who require a ventilator (or high-flow oxygen) and that this recommendation was due to a potential safety issue as well as an unfavorable risk/benefit profile in the trial data. | On October 30, 2020, the company Regeneron announced that an independent data monitoring committee overseeing the clinical trials recommended that the company cease enrolling hospitalized patients who require a ventilator (or high-flow oxygen) and that this recommendation was due to a potential safety issue as well as an unfavorable risk/benefit profile in the trial data. |